Of 22 votes cast so far, The real story is political irony. A year after HHS Secretary RFK Jr. axed roughly $500 million from mRNA vaccine research over doubts about the technology, that same mRNA platform just produced one of oncology's biggest wins in years — proof mRNA's future was never just about COVID shots, and that the funding cuts were shortsighted. leads with 41%.
This was speculation running ahead of the facts. Merck and Moderna hadn't even released the actual numbers — "clinically meaningful improvement" is marketing language, not data. A single day move that nearly triples a company's value, followed by a 25% reversal, looks like hype correcting itself, not a rational re-pricing of a breakthrough. is second on 32%, 9 points behind.
Votes have come in from 2 countries, most of them from China.
The poll is still live and picked up a vote today.